Monte Rosa Therapeutics Inc (GLUE) FinancialsGLUEFinancialMonte Rosa Therapeutics Inc

Evaluating the bottom line, Monte Rosa Therapeutics, Inc. maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -547.84%, while the net margin is -483.91%. These profitability ratios, combined with a Return on Equity (ROE) of -42.66%, provide a clear picture of how effectively GLUE converts its operational activities into shareholder value.

In the context of the broader market, GLUE competes directly with industry leaders such as KURA and ODTX. With a market capitalization of $1.32B, it holds a leading position in the sector. When comparing efficiency, GLUE's gross margin of 100.00% stands against KURA's 98.84% and ODTX's N/A. Such benchmarking helps identify whether Monte Rosa Therapeutics, Inc. is trading at a premium or discount relative to its financial performance.

The company reported a gross margin of 100% consistently over the past quarters, but net income has been negative, with a net loss of $44.5 million in Q1 2026 and $43.4 million in Q2 2026. The forward P/E ratio is 10.8578, suggesting potential for future earnings, but current performance is concerning.